Court lets Eli Lilly's "personalized" advertising claim against Henry Meds proceed

A federal judge in California ruled on September 24 that Eli Lilly can move forward with its claim that telehealth company Henry Meds falsely advertised mass-produced compounded tirzepatide as "personalized" or "patient-specific" ^[1]. At the same time, the judge threw out — for now — Lilly's broader claim that Henry falsely marketed those compounded products as "safe and effective" ^[1].

Tirzepatide is the active ingredient in Lilly's FDA-approved drugs Mounjaro and Zepbound ^[1]. Compounded versions are made by pharmacies and outsourcing facilities rather than by Lilly, and they are not FDA-approved.

What the judge decided

U.S. District Judge Jon S. Tigar of the Northern District of California ruled on Henry's motion to dismiss, a very early stage of a lawsuit where a court decides only whether the allegations, if true, could support a legal claim ^[1]. No one has proven anything yet.

On the personalization question, the court found that Lilly "plausibly alleged" that Henry's use of words like "individualized," "tailored," and "patient-specific" was literally false ^[1]. The reasoning was straightforward: if patients are all receiving the same formula, describing it as individualized could mislead consumers ^[1].

On the "safe and effective" claim, the court sided with Henry, finding that Lilly's allegations amounted to a lack of substantiation rather than a showing that the statements were false ^[1]. In other words, Lilly argued there were no clinical trials backing the claim, but the court said pointing to missing data is not the same as proving a statement untrue ^[1]. The judge gave Lilly permission to amend its complaint and try again on that point ^[1]. If Lilly does not amend, the case moves forward on the personalization issue alone ^[1].

The underlying lawsuit

Lilly filed the suit in April 2025 ^[1]. According to the source, the company alleged that Henry Meds marketed compounded tirzepatide as "the same active ingredient" as Lilly's FDA-approved products, advertised oral tirzepatide as a "patient-specific" treatment when it was actually standardized and mass-produced, and suggested the compounded drugs were "safe and effective" without clinical trials to support that ^[1].

Lilly claimed violations of the federal Lanham Act, which covers false advertising between competitors, along with California's Unfair Competition Law and False Advertising Law ^[1]. The company argued that Henry's messaging diverted patients away from Mounjaro and Zepbound ^[1].

Henry Meds' response to the ruling is not described in the available source, and the court did not rule on whether the compounded products themselves are safe or unsafe ^[1].

Why it matters for patients

Many telehealth companies have described compounded GLP-1 medications using language like "personalized," "customized," or "tailored to you." This ruling signals that courts may read that language literally, and that a marketing term can become a legal issue if the underlying product is standardized and mass-produced ^[1]. The commentary describing the ruling frames it as opening the door to more scrutiny of how telehealth and compounding companies market GLP-1s, particularly when their messaging blurs the line between compounded products and FDA-approved drugs ^[1].

For people comparing options, the practical takeaway is about information, not safety findings. A court allowing a false-advertising claim to proceed is not a determination that any compounded product is dangerous, nor is the dismissal of the "safe and effective" claim a finding that compounded tirzepatide is safe and effective ^[1]. The judge's point was narrower: Lilly had shown a gap in evidence, not proof of falsity ^[1].

It is also worth noting what the source does not resolve. It does not say how the court handled Lilly's separate allegation about "the same active ingredient" marketing, and it does not give a schedule for the rest of the case.

What happens next

Lilly has the option to amend its complaint to revive the "safe and effective" theory ^[1]. The deadline for doing so is not stated in the available source. If Lilly does not amend, the litigation continues only on the personalization claim ^[1]. Any trial date, settlement, or further rulings have not yet been reported in the material available.